SUPPLEMENTARY DATA

Exclusion criteria

The main exclusion criteria were hemorrhagic stroke or history of symptomatic hemorrhagic stroke; presence of high-risk potential cardiac sources of embolism or other determined etiology of stroke based on the Trial of Org 10,172 in Acute Stroke Treatment classification at the time of enrollment; known major hematologic, neoplastic, metabolic, gastrointestinal, or endocrine dysfunction; history of malignancy, except in subjects who had been disease-free >5 years or whose only malignancy has been basal or squamous cell skin carcinoma; life-threatening illness indicating that the subject is not expected to survive for at least 2 years; secondary causes of nephrotic syndrome and/or renal dysfunction (serum creatinine >2.0 mg/dL); uncontrolled hypertension defined as either a resting systolic blood pressure >185 mmHg or resting diastolic blood pressure >110 mmHg despite blood pressure lowering therapy; clinically significant heart disease likely to require coronary artery bypass surgery, cardiac transplantation, surgical repair, and/or valve replacement during the course of the study (within 14 days after enrollment); moderate or greater severity of congestive heart failure (New York Heart Association Class III or IV) or whose most recent determination of left ventricular ejection fraction was <0.35; triglyceride level >500 mg/dL; low-density lipoprotein (LDL) cholesterol level >190 mg/dL; creatine kinase >3 times the upper limit of normal range (ULN); aspartate aminotransferase, alanine aminotransferase, or bilirubin levels >3 times the ULN; thyroid stimulating hormone >1.5 times the ULN; modified Rankin scale score 4-6 before stroke; possible need for conventional angiography, intervention, or carotid artery surgery during the course of the study; known serious hypersensitivity reactions to HMG-CoA reductase inhibitors; and history of myopathy.

Conduct of study

The first patient was enrolled in August 2010, and the study was scheduled to complete enrollment in August 2012. However, in June 2013 the study was stopped early due to slow enrollment. All patient data were recorded on standardized data-collection forms by an investigator or coordinator who was unaware of study-group assignments. All data were subsequently entered into a web-based clinical data management system and managed by an independent data management service (ADM Korea Inc., Seoul, Korea).

Supplemental Table 1. Changes in lipid profiles before and after treatment

	Rosuvastatin (n=155)	Placebo (n=159)	*P* value
Total cholesterol			
Baseline	196.8±37.6	185.9±33.4	0.008
Closing	125.4±25.5	183.2±34.6	<0.001
Change	-69.2±34.2	-3.7±36.5	<0.001
HDL cholesterol			
Baseline	44.5±10.0	44.3±12.3	0.603
Closing	43.3±10.6	41.9±12.4	0.194
Change	-1.5±9.0	-2.2±12.1	0.477
LDL cholesterol			
Baseline	129.8±33.0	119.9±29.7	0.006
Closing	63±22.8	115.1±31.3	<0.001
Change	-63.9±30.4	-5.8±31.3	<0.001
Triglyceride			
Baseline	128.3±76.7	132.6±65.9	0.191
Closing	111.9±51.0	165±100	<0.001
Change	-20.7±73.2	29.2±86.1	<0.001

HDL, high-density lipoprotein; LDL, low-density lipoprotein.

http://dx.doi.org/10.5853/jos.2015.01578

Supplemental Table 2. Characteristic of excluded patients from mITT

	Excluded from mITT (n=25)			Excluded from mITT (n=25)		
	Excluded from mITT (n=25)	Included in mITT (n=289)	*P*	Rosuvastatin 20 mg (n=18)	Placebo (n=7)	*P*
Demographics						
Sex (male)	14 (56.0)	174 (60.2)	0.842	9 (50.0)	5 (71.4)	0.407
Age (year)	67.4±11.8	64.8±11.8	0.299	65.7±11.1	71.7±13.4	0.260
Body mass index (kg/m^2)	23.2±3.3	24.0±3.0	0.184	23.4±3.1	22.5±3.7	0.551
Abdominal circumference (cm)	85.3±8.2	86.8±9.4	0.457	85.9±7.7	83.8±10.1	0.612
Past history						
Hypertension	19 (76.0)	187 (64.7)	0.357	13 (72.2)	6 (85.7)	0.627
Diabetes mellitus	12 (48.0)	89 (30.7)	0.123	9 (50.0)	3 (42.8)	1.000
Hypercholesterolemia	6 (24.0)	44 (15.2)	0.256	5 (27.7)	1 (14.2)	0.627
Smoking	17 (68.0)	158 (54.6)	0.281	12 (66.6)	5 (71.4)	1.000
Coronary artery occlusive disease	2 (8.0)	3 (1.0)	0.053	1 (5.5)	1 (14.2)	0.49
Peripheral artery occlusive disease	1 (4.0)	1 (0.3)	0.153	1 (5.5)	0 (0.0)	1.000
Previous stroke	6 (24.0)	23 (7.9)	0.019	4 (22.2)	2 (28.5)	1.000
Concomitant medication						
Antihypertensive	14 (56.0)	126 (43.5)	0.324	9 (50.0)	5 (71.4)	0.407
Antiplatelet			0.913			0.735
Aspirin	5 (20.0)	73 (25.2)		3 (16.6)	2 (28.5)	
Clopidogrel	2 (8.0)	17 (5.8)		1 (5.5)	1 (14.2)	
Aspirin and clopidogrel	16 (64.0)	164 (56.7)		12 (66.6)	4 (57.1)	
Aspirin and cilostazol	1 (4.0)	13 (4.4)		1 (5.5)	0 (0.0)	
Aspirin, clopidogrel, and cilostazol	1 (4.0)	22 (7.6)		1 (5.5)	0 (0.0)	
Anticoagulant	0 (0.0)	1 (0.3)	1.000	0 (0.0)	0 (0.0)	
Lipid-lowering drug (other than statin)	1 (4.0)	2 (0.6)	0.221	1 (5.5)	0 (0.0)	1.000
Diabetes mellitus drug	11 (44.0)	58 (20.0)	0.010	8 (44.4)	3 (42.8)	1.000
NSAID	3 (12.0)	18 (6.2)	0.228	2 (11.1)	1 (14.2)	1.000
Intravenous tPA	1 (4.0)	8 (2.7)	0.531	0 (0.0)	1 (14.2)	0.28
Baseline DWI volume (mm^3)	542.4 [203.5-4115.3]	710 [259.1-2803.6]	0.254	640.2 [223.7-4664.8]	221.5 [27.9-595.9]	0.049
Baseline NIHSS	4 [2-5]	3 [1-6]	0.206	3.5 [2-5]	4 [2-8]	0.544
Lab						
White blood cells (×10^3/μL)	7.898±2.436	7.982±2.325	0.896	8.248±2.74	6.997±1.075	0.296
Neutrophils (×10^3/μL)	60.664±10.556	61.921±17.159	0.242	61.1±10.686	59.543±10.96	0.743
Hemoglobin (g/dL)	13.480±1.720	14.018±1.590	0.098	13.461±1.716	13.529±1.867	0.936
Hematocrit (%)	39.416±4.776	41.158±4.424	0.054	39.656±5.024	38.8±4.369	0.737
Platelet count (×10^3/μL)	238.96±74.077	243.474±62.062	0.630	253.167±81.4	202.429±31.837	0.086
BUN (mg/dL)	16.108±5.354	15.236±5.38	0.387	15.444±4.93	17.814±6.41	0.388
Creatinine (mg/dL)	0.894±0.296	0.844±0.226	0.399	0.807±0.198	1.116±0.399	0.020
Fasting glucose (mg/dL)	137.656±60.42	133.711±57.247	0.728	131.411±47.397	153.714±88.428	0.556
Albumin (g/dL)	4.012±0.461	4.127±0.336	0.200	3.978±0.479	4.1±0.432	0.544
Uric acid (mg/dL)	5.146±1.616	5.052±1.429	0.812	4.831±1.609	5.957±1.427	0.088
hsCRP (mg/dL)	2.843±6.94	2.266±6.955	0.783	2.79±7.423	2.98±6.042	0.956

Values are number (%), mean±standard deviation, or median [interquartile range].
mITT, modified intention-to-treat; NSAID, indicates nonsteroidal anti-inflammatory drug; t-PA, tissue plasminogen activator; DWI, diffusion-weighted imaging; NIHSS, National Institute of Health Stroke Scale; hsCRP, high sensitivity C-reactive protein; BUN, blood urea nitrogen.